Competitive Intelligence
- Which competitor benefit claims are gaining support and spreading?
- Is a disputed positioning claim stabilising across independent sources?
Respond while the shift is forming, not once it is priced in.
For your team
Four teams. One question: Has the accepted position caught up with the evidence?
All four reconstruct the same thing by hand — first appearance, wording changes, evidence attached, whether a claim held or spread. We run it across a therapeutic area and return the source-linked record for review.
Buyer use cases
What each team can answer.
Medical Affairs & Evidence Strategy
- Which claims about your drug are losing qualifiers and hardening?
- Which remain contested, and where is the evidence not keeping up?
Plan evidence against where the record actually sits.
Business Development & Diligence
- Was the current consensus recent or durable — and was it contested?
- Are the claims that matter still moving, or have they settled?
Price the asset on how settled its record is.
Market Access & Regulatory Strategy
- Where is public representation running ahead of formal policy?
- Is authority language appearing in public sources before formal action?
Start scenario work while the gap is still open.
Against your own calendar
Where it lands against the deadline you already have.
Your milestones, not ours. The horizons here are illustrative; how much warning a given claim affords depends on the record behind it.
Operational Utility Illustrative Horizon Framework
What useful lead time enables across your review calendar
Medical change moves along a documented trajectory months before formal determination. Trajectory intelligence converts that window into structured operational readiness across your teams.
Proactive Preparation
With Trajectory Intelligence
- ▸ Identify emerging subgroup benefit and biomarker criteria from newly replicated trials prior to guideline drafts.
- ▸ Commission targeted real-world evidence (RWE) analyses to evaluate observational durability within published cohorts.
- ▸ Update budget-impact and comparative cost-effectiveness models before society scoping closes.
The Reactive Reality
Relying on Document Alerts
Caught off guard when clinical society draft guidelines enter public comment without your economic inputs.
Decision Lag Impact Planning window lost
Proactive Preparation
With Trajectory Intelligence
- ▸ Revise AMCP dossiers and Global Value Dossiers (GVD) with harmonized diagnostic thresholds prior to committee review.
- ▸ Brief clinical trial investigators and society guideline panel members on real-world safety data within the review window.
- ▸ Assemble comprehensive evidence reads for upcoming P&T committee cycles.
The Reactive Reality
Relying on Document Alerts
Forced into a hurried scramble trying to synthesize trial sub-analyses after a draft grade drop.
Decision Lag Impact Planning window lost
Proactive Preparation
With Trajectory Intelligence
- ▸ Engage regional commercial and Medicare Advantage plans on restrictive prior authorization criteria.
- ▸ Clarify biomarker confirmation protocols to prevent unwarranted step-therapy hurdles prior to policy lock.
- ▸ Align value-based contracting terms against expected formal restriction language within the decision window.
The Reactive Reality
Relying on Document Alerts
Payer policy updates lock in restrictive prior-authorization step-edits across regional formularies for the upcoming cycle.
Decision Lag Impact Planning window lost
Proactive Preparation
With Trajectory Intelligence
- ▸ Execute immediate market access launch aligned with published guideline grade or LCD terms.
- ▸ Field teams deploy pre-cleared medical science liaison (MSL) materials on day one after publication.
- ▸ Initiate computational re-review diff against baseline evidence map on demand.
The Reactive Reality
Relying on Document Alerts
Prolonged delays in patient access while internal teams scramble to assemble retrospectively required dossiers.
Decision Lag Impact Immediate delay in access
12 months out · Illustrative Evidence gaps
- Point RWE work at the claims that are moving
- Brief KOLs before guideline drafting opens
6 months out · Illustrative Dossier and committee prep
- Answer persisting claims in P&T dossiers
- Align regional teams on converging authority language
3 months out · Illustrative Rapid response
- File formulary packages with the evidence attached
- Draft field responses for the contested claims only
Regional coverage
Mapped to regional authority frameworks.
Claims are structured against the bodies that decide in each market.